Assessment of Risk Factors for Atherosclerosis in Individuals of Different Categories of Cardiovascular Risk Using the Aterostop Calculator

Aim        To analyze first results of using the Aterostop calculator for a comprehensive evaluation of the risk for cardiovascular diseases (CVD).

Material and methods        A cross-sectional study analyzed major and additional risk factors in 460 subjects without apparent disease and in patients with documented CVD of atherosclerotic origin using the application (calculator) Aterostop developed in the National Medical Research Center of Cardiology in Moscow, Russia.

Results   45.4% of evaluated persons belonged to the categories of very high and extreme risk. Age and frequencies of smoking, arterial hypertension, and diabetes mellitus (DM) increased with the increase in risk; the growth of DM was exponential. 129 (28%) individuals used lipid-lowering medications at the time of study. Their plasma levels of low-density lipoprotein cholesterol (LDL-C) were significantly lower than in those who did not received this treatment. However, achieving the target level was inversely proportional to the risk: the greatest proportion of individuals who reached the LDL-C target was in the category of low risk and the smallest proportion was in the category of extreme risk (75 % vs. 3.7 %, respectively).

Conclusion            The results obtained with the calculator Aterostop were consistent with earlier reports of insufficient effectiveness of primary and secondary prevention of atherosclerotic CVDs, which requires more tight and fruitful cooperation of the physician and the patient.

1. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, LuengoFernandez R et al. European cardiovascular disease statistics 2017 edition. European Heart Network, Brussels. Av at: http://www.ehnheart.org/images/CVD-statistics-report-August-2017.pdf. 2017. [192p]

2. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber Al an J et al. American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease - Executive Summary. Endocrine Practice. 2017;23(4):479–97. DOI: 10.4158/EP171764.GL

3. Sergienko I.V., Ansheles A.A., Boytsov S.A. Mobile application “Aterostop” for a comprehensive assessment of cardiovascular risk in patients in the Russian population. Therapeutic Archive. 2021;(in press).

4. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Bubnova M.G., Balakhonova T.V. et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Atherosclerosis and dyslipidemia. 2020;1(38)):7–40. DOI: 10.34687/2219-8202.JAD.2020.01.0002

5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455

6. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology. 2019;26(8):824–35. DOI: 10.1177/2047487318825350

7. Oganov R.G., Kukharchuk V.V., Arutyunov G.P., Galyavich A.S., Gurevich V.S., Duplyakov D.V. et al. Persistent dyslipidemia in statintreated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70–8. DOI: 10.15829/1728-8800-2012-4-70-78